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Introduction
T cell receptor (TCR) recognition of tumor antigen is
essential for effective antitumor immunity. The immune
system`s ability to respond to a broad spectrum of anti-
gens requires a sophisticated selection of various TCR.
So far, little is known about the role of TCR richness and
clonality in the immune response to the EGFR-specific
mAb, cetuximab. Therefore, we investigated differences
in TCR sequences between HPV+ and HPV- patients, as
well as differences in sequence characteristics between
T cells of peripheral blood mononuclear cells (PBMC)
and tumor infiltrating lymphocytes (TIL). Additionally,
we were able to investigate the TCR richness and clonal-
ity in samples pre- and post-treatment in a clinical single
agent cetuximab trial.
Material and methods
TCR genotyping was performed and quantified by Adap-
tive Technologies, Inc (Seattle, WA). Richness (S) was
defined as total number of unique productive sequences.
The Shannon Index is defined as H=-log∑pi(1-pi), pi is
the proportion of sequence i relative to the total
sequences. The clonality is defined as 1-H/log(S). The
maximum available number of samples from the same
patient was 4, containing pre- and post-treatment PBMC
and pre- and post-treatment TIL. Paired comparisons
(pre vs. post) were done using the Wilcoxon Signed Rank
tests. Comparisons between two independent groups (i.e.
HPV+ vs. HPV-, or responders vs. non-responders) were
accomplished with Wilcoxon Rank Sum tests.
Results
Using a cohort of neoadjuvant, single-agent cetuximab
treated HNSCC patients, 56 samples were analyzed for
global TCR diversity. HPV+ and HPV- patients did not
significantly differ in clonality and richness pre- and
post-treatment in either PBMC or TIL. However, cetuxi-
mab therapy significantly increased the richness of
unique sequences in PBMC (p=0.0002). Most impor-
tantly, the responder group had a higher increase of
richness post-treatment in PBMC. The difference
reached a p-value of 0.03 post-treatment. On the con-
trary, this increase was not observed in TIL, which
appeared to be more focused after cetuximab therapy.
Discussion
TCR clonality and richness for PBMC and TIL seem to be
independent from the patient’s HPV status in HNSCC.
Intriguingly, an increase in richness of TCR sequences in
the periphery (PBMC) but a focusing in TIL was associated
with an improved treatment response, suggesting an influ-
ence of peripheral quantity on intratumoral TCR quality.
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